Drug Trial Radar · NCT01896232
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
Last checked: Nov 20, 2026Latest source record: Jul 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
683
Actual
Start
Aug 13, 2013
Primary completion
Nov 12, 2014
Study completion Jan 8, 2015
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jul 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum parathyroid hormone (PTH) levels by \> 30% from baseline among patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) who require management with hemodialysis.
Conditions
- Secondary Hyperparathyroidism
- Chronic Kidney Disease
Interventions
EtelcalcetideDrug
Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.
CinacalcetDrug
Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.
Oral PlaceboDrug
Administered orally once a day.
Intravenous PlaceboDrug
Administered intravenously (IV) three times per week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With > 30% Reduction From Baseline in Mean Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority AnalysisTime frame: Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).
Locations
182 sites in 22 countries. Site status is shown where the registry gives one.
Research Site
Azusa, California
Research Site
Bakersfield, California
Research Site
Bakersfield, California
Research Site
Chula Vista, California
Research Site
Covina, California
Research Site
Granada Hills, California
Research Site
La Mesa, California
Research Site
La Puente, California
Research Site
Los Angeles, California
Research Site
San Diego, California
Research Site
San Gabriel, California
Research Site
Whittier, California
Research Site
Arvada, Colorado
Research Site
Aurora, Colorado
Research Site
Longmont, Colorado
Research Site
Westminster, Colorado
Research Site
Orange, Connecticut
Research Site
Pembroke Pines, Florida
Research Site
Pinecrest, Florida
Research Site
Tampa, Florida
Research Site
Baton Rouge, Louisiana
Research Site
Lafayette, Louisiana
Research Site
Southgate, Michigan
Research Site
Columbus, Mississippi
Research Site
Gulfport, Mississippi
Research Site
Sewell, New Jersey
Research Site
Great Neck, New York
Research Site
Mineola, New York
Research Site
Ridgewood, New York
Research Site
Rosedale, New York
Research Site
The Bronx, New York
Research Site
Wilmington, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Columbus, Ohio
Research Site
Philadelphia, Pennsylvania
Research Site
Houston, Texas
Research Site
San Antonio, Texas
Research Site
Burlington, Vermont
Research Site
Fairfax, Virginia
Research Site
Portsmouth, Virginia
Showing 40 of 182 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.